Gilead Sciences Inc - Company Profile
Powered by 
All the data and insights you need on Gilead Sciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Gilead Sciences Inc Strategy Report
- Understand Gilead Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreGilead Sciences Regulatory Milestones
Track drug and patent expiries along with geographies impacted.
A sample of Gilead Sciences Regulatory Milestones data
| Drug Name | Generic Name | Brand Name | Company Name | Expiry Geography | Constraining Patent Number | Constraining Patent Expiry | Drug Expiry (Estimated) | Highest Development Stage |
|---|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem | Lorem | Lorem | Pfizer Inc | Lorem | WXYZ | Lorem | Pending | Lorem |
| MB-272 | - | - | MiroBio Ltd | United States | US11421030 | Feb-2040 | - | - |
| (cilofexor + firsocostat) | (cilofexor [INN] + firsocostat) | - | Gilead Sciences Inc | Japan | JP2022524398 | - | Pending | - |
| Gene Therapy to Target BCMA for Multiple Myeloma | - | - | Gilead Sciences Inc | United States | US10689450 | Mar-2037 | - | - |
A sample of Gilead Sciences Inc Review Designation data
| Drug Name | Generic Name | Company Name | Indication | Geography | Designation Type | Designation Status | Designation Date |
|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | Lorem | Pfizer Inc | Lorem | Lorem | Lorem | Lorem | 27 Sep 2022 |
| brexucabtagene autoleucel | brexucabtagene autoleucel | Kite Pharma EU BV | B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) | EU | Orphan Drug Designation | Designated/Approved | 19 Oct 2020 |
| brexucabtagene autoleucel | brexucabtagene autoleucel | Kite Pharma Inc | Mantle Cell Lymphoma | United States | Priority Review | Designated/Approved | 10 Feb 2020 |
| brexucabtagene autoleucel | brexucabtagene autoleucel | Kite Pharma Inc | Mantle Cell Lymphoma | United States | Breakthrough Therapy | Designated/Approved | 09 Dec 2019 |
Feature
Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.
Benefit
Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.
The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.
The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.
US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).
Value
Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .
Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer